Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Learn more about us at www.madrigalpharma.com
Looking for a particular Madrigal Pharmaceuticals employee's phone or email?
Madrigal Pharmaceuticals Questions
The Madrigal Pharmaceuticals annual revenue was $180.1 million in 2026.
Bill Sibold is the CEO of Madrigal Pharmaceuticals.
651 people are employed at Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals is based in Conshohocken, Pennsylvania.
The NAICS codes for Madrigal Pharmaceuticals are [3254, 541, 54, 325, 32541, 32].
The SIC codes for Madrigal Pharmaceuticals are [87, 28, 873, 283].
Top Madrigal Pharmaceuticals Employees
-
Bill Sibold
Chief Executive Officer at Madrigal Pharmaceuticals
Cambridge, MA, US25+ -
Paul Friedman
CEO at Madrigal Pharmaceuticals
Conshohocken, PA, US11 -
35+
-
23
-
Uli Frevert
VP Translational Medicine at Madrigal Pharmaceuticals
Princeton, NJ, US33 -
25+
-
45+
Related Companies
